In patients with advanced-stage myeloid malignancies, treatment with 5-aza led to a significant decrease of IL-4 secreting CD4+ T cells, and a significant increase of IL-17A- and IL-21-secreting CD4+ T cells in the peripheral blood. The gene discussed is CD4; the disease is myeloid neoplasm.